Thus a study was undertaken to investigate the promoter hypermethylation status of HOXA4 in CML patients on IM treatment and to determine its role in mediating resistance to IM. The gene discussed is HOXA4; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.